ARCOMA Arcoma AB

Arcoma wins important procurement in Finland. (MAR)

Arcoma wins important procurement in Finland. (MAR)

2022-06-27

PRESSRELEASE

Arcoma wins important procurement in Finland.



Arcoma AB has won important procurement of up to 6 Arcoma Precision i5 systems to “HUS Medical Imaging Center” in Finland. Three of the systems will be installed in 2022 and the contract has an option for three more systems for installation in 2023. The total order value is up to approximately SEK 7.5 million, depending on options.

The procurement was won by Lifemed Medical Systems, which is Arcoma's distributor and partner in Finland, and the end customer is the “HUS Medical Imaging Center”, which is part of Helsinki University Hospital.

"We are very pleased for this opportunity to supply these systems to HUS, together with our long-term partner Arcoma. Ergonomics, patient safety and good image quality were they key factors in this tender and Precision i5 is a perfect solution to address these needs”, says Mikko Isoviita, Sales Manager Lifemed Medical Systems.

"It is great that we through Lifemed have won this procurement, it is an important customer and very good reference hospitals for Arcoma", says Tarik Cengiz, Business Director & Key Account Manager at Arcoma AB.



About Lifemed

Lifemed Medical Systems is a Finnish family-owned company that offers high-quality medical imaging systems and a wide range of other healthcare equipment and accessories. They have over 30 years of experience in the field and their clients include both public and private care providers and educational institutions throughout Finland.



About Arcoma

Arcoma, with long experience in the industry, is a leading provider of integrated digital X-ray systems with high quality and advanced technology. Arcoma’s products offer the latest digital imaging technology combined with technically advanced moving positioning systems and ergonomic Scandinavian design. Arcoma offers the customers complete, configurable and functional digital x-ray systems. The company's products are sold through retailers as well as OEM customers and today there are over 3,500 of Arcoma’s X-ray systems installed worldwide. Arcoma is listed on Nasdaq First North. For more information about Arcoma, please visit



For more information, please contact:

Sanna Rydberg, Phone: +46 706 069548, E-mail: . The information was submitted, through the CEO, for publication on June 27, 2022 at 1 PM.

For more IR-related information and the possibility of pressrelease prenumeration, please visit our IR page:



This information is such information that Arcoma AB is obliged to publish in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, through the CEO, for publication on June 27, 2022 at 1 PM.

Attachment



EN
27/06/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Arcoma AB

 PRESS RELEASE

Arcoma avslutar avtal om likviditetsgaranti

Arcoma avslutar avtal om likviditetsgaranti PRESSRELEASE 2025-06-30 Arcoma avslutar avtal om likviditetsgaranti Arcoma har avslutat avtalet med DNB Carnegie Investment Bank AB, där DNB Carnegie har verkat som likviditetsgarant för bolaget. Syftet med garantin har varit att främja likviditeten i bolagets aktie, minska volatiliteten samt underlätta handel. Arcoma bedömer att rådande handel och därmed likviditeten i aktien är god och att behovet av en likviditetsgarant är begränsad. DNB Carnegies uppdrag avslutas tisdag den första juli 2025. Om Arcoma Arcoma, med lång erfarenhet av brans...

 PRESS RELEASE

Arcoma AB successfully completes directed share issue of SEK 11.0 mill...

Arcoma AB successfully completes directed share issue of SEK 11.0 million (~ EUR 1 million) (MAR) Arcoma AB successfully completes directed share issue of SEK 11.0 million (~ EUR 1 million) NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE CONTRAVENING TO ANY APPLICABLE RULES OR REQUIRE REGISTRATION OR OTHER ACTIONS. PLEASE REFER...

 PRESS RELEASE

Arcoma AB har framgångsrikt genomfört en riktad nyemission om 11,0 MSE...

Arcoma AB har framgångsrikt genomfört en riktad nyemission om 11,0 MSEK (~1 MEUR) (MAR) Arcoma AB har framgångsrikt genomfört en riktad nyemission om 11,0 MSEK (~1 MEUR) EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARKEN DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE VARA OLAGLIG ELLER KRÄVA YTTERLIGARE REGISTRERINGS- ELLER ANDRA ÅTGÄRDER. SE AVSNITTET "VIKTIG INFOR...

 PRESS RELEASE

Kommuniké från årsstämma i Arcoma Aktiebolag den 14 maj 2025

Kommuniké från årsstämma i Arcoma Aktiebolag den 14 maj 2025 PRESSRELEASE 2025-05-14 Kommuniké från årsstämma i Arcoma Aktiebolag den 14 maj 2025 Idag, den 14 maj 2025, hölls årsstämma i Arcoma Aktiebolag. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet. Beslut om fastställande av räkenskaper samt resultatdispositionÅrsstämman beslutade att fastställa resultat- och balansräkning samt koncernresultat- och koncernbalansräkning. Årsstämman beslutade även att disponera över bolagets resultat ienlighet med styrelsens förslag i årsr...

 PRESS RELEASE

Kvartalsrapport Q1 2025 – Stark efterfrågan, installationstakt i USA d...

Kvartalsrapport Q1 2025 – Stark efterfrågan, installationstakt i USA dämpar kvartalet något. (MAR) PRESSRELEASE 2025-04-29 Kvartalsrapport Q1 2025 – Stark efterfrågan, installationstakt i USA dämpar kvartalet något. (MAR) FINANSIELLT SAMMANDRAG Första kvartalet Nettoomsättningen för kvartalet uppgick till 34 875 (46 464) kSEK EBITDA (rörelseresultat före avskrivningar) uppgick till 4 458 (6 493) kSEK EBITDA-marginalen uppgick till 12% (14%)Resultat före skatt uppgick till 2 582 (4 502) kSEKResultat per aktie 0,16 (0,27) SEK VIKTIGA HÄNDELSER I PERIODEN• Inga händelser att rapportera. ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch